A forum of leading hepatologists, endocrinologists and clinical development experts stewarding advances in science, clinical research and therapeutics for nonalcoholic fatty liver disease and steatohepatitis
Because of the impacts of COVID-19, plans for NASH Roundtable meetings in 2021 are still under consideration. Please contact us with questions.
Fact Sheet: NASH Roundtable, leading clinical development experts addressing challenges in NASH drug developmentView Fact Sheet »
MEMBER CO-AUTHORED PUBLICATIONS
Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease. Read More »
Implications of Abdominal Adipose Tissue Distribution on Nonalcoholic Fatty Liver Disease and Metabolic Syndrome: A Chinese General Population Study. Read More »
Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in five european countries in 2018: A cost-of-illness analysis. Read More »
A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH. Read More »